Invest in Cara Therapeutics Inc. (CARA) to keep your portfolio healthy

After finishing at $5.76 in the prior trading day, Cara Therapeutics Inc. (NASDAQ: CARA) closed at $5.78, up 0.35%. In other words, the price has increased by $+0.02 from its previous closing price. On the day, 535943 shares were traded. CARA stock price reached its highest trading level at $5.87 during the session, while it also had its lowest trading level at $5.51.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



Our goal is to gain a better understanding of CARA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.10 and its Current Ratio is at 7.20. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on March 08, 2023, Downgraded its rating to Underperform and sets its target price to $6 from $13 previously.

On March 08, 2022, JP Morgan Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $17 to $20.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 03 when Menzaghi Frederique Ph.D. sold 6,802 shares for $9.71 per share. The transaction valued at 66,047 led to the insider holds 159,473 shares of the business.

Terrillion Scott sold 6,256 shares of CARA for $60,746 on Mar 03. The Sec’y; Chief Compliance & G.C. now owns 93,527 shares after completing the transaction at $9.71 per share. On Mar 03, another insider, Goncalves Joana, who serves as the Chief Medical Officer of the company, sold 6,221 shares for $9.71 each. As a result, the insider received 60,406 and left with 58,885 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 7.85 while its Price-to-Book (P/B) ratio in mrq is 1.96.

Stock Price History:

Over the past 52 weeks, CARA has reached a high of $13.97, while it has fallen to a 52-week low of $5.43. The 50-Day Moving Average of the stock is 10.29, while the 200-Day Moving Average is calculated to be 10.10.

Shares Statistics:

The stock has traded on average 572.52K shares per day over the past 3-months and 1.47M shares per day over the last 10 days, according to various share statistics. A total of 53.76M shares are outstanding, with a floating share count of 45.04M. Insiders hold about 0.50% of the company’s shares, while institutions hold 66.80% stake in the company. Shares short for CARA as of Jan 30, 2023 were 5.36M with a Short Ratio of 5.49M, compared to 4.96M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 9.97% and a Short% of Float of 14.12%.

Earnings Estimates

Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.32 for the current quarter, with a high estimate of -$0.22 and a low estimate of -$0.48, while EPS last year was -$0.63. The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.17 and low estimates of -$0.28.

Analysts are recommending an EPS of between -$1.24 and -$1.51 for the fiscal current year, implying an average EPS of -$1.35. EPS for the following year is -$0.6, with 8 analysts recommending between $0.32 and -$1.19.

Revenue Estimates

7 analysts predict $16.37M in revenue for the current quarter. It ranges from a high estimate of $18.2M to a low estimate of $14.2M. As of the current estimate, Cara Therapeutics Inc.’s year-ago sales were $821k, an estimated increase of 1,893.90% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $20.88M, an increase of 335.90% less than the figure of $1,893.90% in the same quarter last year. There is a high estimate of $22.5M for the next quarter, whereas the lowest estimate is $19.27M.

A total of 8 analysts have provided revenue estimates for CARA’s current fiscal year. The highest revenue estimate was $56.81M, while the lowest revenue estimate was $51M, resulting in an average revenue estimate of $54.71M. In the same quarter a year ago, actual revenue was $23.03M, up 137.60% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $120.89M in the next fiscal year. The high estimate is $175.2M and the low estimate is $68.9M. The average revenue growth estimate for next year is up 121.00% from the average revenue estimate for this year.